Surv-CRM-12: a Bayesian phase I/II survival CRM for right-censored toxicity endpoints with competing disease progression

DOI10.1002/SIM.9591zbMATH Open1547.62126MaRDI QIDQ6629418

Shing M. Lee, [[Person:6068877|Author name not available (Why is that?)]], Sylvie Chevret, Anaïs Andrillon

Publication date: 30 October 2024

Published in: Statistics in Medicine (Search for Journal in Brave)

zbMATH Keywords

survival datacompeting risksdose-findingoncologyphase I/II

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Cites Work

• A class of k-sample tests for comparing the cumulative incidence of a competing risk
• Dose-Finding Designs for HIV Studies
• Robust EM Continual Reassessment Method in Oncology Dose Finding
• Sequential Implementation of Stepwise Procedures for Identifying the Maximum Tolerated Dose
• A nonidentifiability aspect of the problem of competing risks.
• Continual Reassessment Method: A Likelihood Approach
• A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials
• Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
• Simple benchmark for complex dose finding studies
• Competing risks as a multi-state model
• Non-parametric optimal design in dose finding studies
• Direct Parametric Inference for the Cumulative Incidence Function
• A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes
• Seamless phase I/II design for novel anticancer agents with competing disease progression

This page was built for publication: Surv-CRM-12: a Bayesian phase I/II survival CRM for right-censored toxicity endpoints with competing disease progression

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6629418)